US 12,215,173 B2
Kappa opioid receptor peptide amide ligands
Subo Liao, Ballwin, MO (US); Jun Yang, Ballwin, MO (US); Jinliang Lv, Yichang (CN); Zongquan Liao, Yichang (CN); Hao Zhou, Yichang (CN); Jueyuan Gao, Yichang (CN); Tianpeng Xie, Yichang (CN); Quanli Yang, Yichang (CN); Lei Wang, Wuhan (CN); and Zejian Ding, Wuhan (CN)
Assigned to Humanwell Pharmaceutical US, Inc., Ballwin, MO (US); and Yichang Humanwell Pharmaceuticals Co. Ltd., Yichang (CN)
Filed by Humanwell Pharmaceutical US, Ballwin, MO (US)
Filed on Aug. 7, 2020, as Appl. No. 16/988,229.
Claims priority of provisional application 62/883,916, filed on Aug. 7, 2019.
Prior Publication US 2021/0040150 A1, Feb. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 5/107 (2006.01); A61K 38/00 (2006.01)
CPC C07K 5/1016 (2013.01) [A61K 38/00 (2013.01)] 2 Claims
 
1. A kappa opioid receptor peptide ligand of Formula (I) or a salt thereof:
A1-A2-A3-A4-B   Formula (I),
wherein A1 is D-phenylalanine, A2 is D-phenylalanine, A3 is D-leucine, A4 is D-lysine, and B is selected from the group consisting of:

OG Complex Work Unit Chemistry
wherein custom character represents the connection to A4.